---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References"
description: "Reference list for the formulary evidence report on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration. 167 cited documents."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References

<a id="references"></a>

## 5 References

1. [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)
2. [Age-Related Eye Disease Study 2 Research Group (2013)](https://pubmed.ncbi.nlm.nih.gov/23644932/)
3. [Age-Related Eye Disease Study Research Group (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1462955/)
4. [Ahluwalia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33742280/)
5. [American Academy of Ophthalmology IRIS63 measure specification](https://www.aao.org/medicare/quality-reporting-measure/iris63-exudative-age-related-macular-degeneration)
6. [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)
7. [American Academy of Ophthalmology MIPS 2024 quality changes (2023)](https://www.aao.org/eyenet/article/mips-2024-what-s-new-with-quality)
8. [Anegondi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39581330/)
9. [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)
10. [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)
11. [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)
12. [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)
13. [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)
14. [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)
15. [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)
16. [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)
17. [Annexon Biosciences Form 10-K (2021)](https://www.sec.gov/Archives/edgar/data/1528115/000156459021015262/annx-10k_20201231.htm)
18. [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)
19. [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)
20. [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial)
21. [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)
22. [Annexon Biosciences PDC pilot press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-selected-ema-participate-product-development-coordinator)
23. [Annexon Biosciences PRIME press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-receives-prime-designation-ema-anx007-treatment)
24. [Annexon Biosciences Retina Society press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-present-patient-baseline-characteristics-vonaprument)
25. [Annexon Biosciences second-quarter 2022 results press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-highlights-business-and-portfolio-progress)
26. [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)
27. [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)
28. [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)
29. [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)
30. [Baker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13546186/)
31. [Bakri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/)
32. [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)
33. [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf)
34. [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)
35. [Bhavsar et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42534291/)
36. [Borkar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39571793/)
37. [Borkar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13226300/)
38. [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)
39. [Boyer et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10885856/)
40. [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)
41. [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)
42. [Caswell et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8319273/)
43. [Centers for Medicare & Medicaid Services Quality ID 14 (2023)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_014_MIPSCQM.pdf)
44. [Chakravarthy (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Chakravarthy-Euretina.pdf)
45. [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)
46. [Chakravarthy et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-Chakravarthy-FINAL.pdf)
47. [Chang (2026)](https://annexonbio.com/wp-content/uploads/2026/07/MChang-ASRS-Presentation-FINAL-18Jul26.pptx.pdf)
48. [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)
49. [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)
50. [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)
51. [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)
52. [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)
53. [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)
54. [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)
55. [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/76a714ad-3a2c-43ac-b76d-9dadf8f7d890/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)
56. [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)
57. [Colijn et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5755466/)
58. [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)
59. [Cummings Joyner et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/133629)
60. [Danzig et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38719191/)
61. [Dhoot et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665201/)
62. [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)
63. [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)
64. [Epshtein (2026)](https://annexonbio.com/wp-content/uploads/2026/09/Epshtein-AAOptom-Poster-.pdf)
65. [Eriksen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11736733/)
66. [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)
67. [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf)
68. [European Medicines Agency Izelvay (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/izelvay)
69. [European Medicines Agency Syfovre (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre)
70. [Evans and Lawrenson (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10498493/)
71. [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)
72. [Fernández-Muro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13708414/)
73. [Fidler (2023)](https://www.biopharmadive.com/news/astellas-iveric-fda-approval-geographic-atrophy-izervay/690052/)
74. [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)
75. [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)
76. [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)
77. [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)
78. [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)
79. [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)
80. [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)
81. [Guymer et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7218279/)
82. [Heier et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32199866/)
83. [Heier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37865470/)
84. [Heier et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Heier-FloRetina-Final-Dec-2024.pdf)
85. [Holekamp et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32081489/)
86. [Holz et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24433969/)
87. [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)
88. [Jackson et al. (2023)](https://aao.org/Assets/354efadd-457b-4f59-a2ac-66beb0253b72/638070751054170000/vision-rehabilitation-ppp-pdf)
89. [Jaffe et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32882310/)
90. [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf)
91. [Jaffe et al. (2024b)](https://annexonbio.com/wp-content/uploads/2024/09/Retina-2024-FINAL-9Sept24.pdf)
92. [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)
93. [Jiao et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6102844/)
94. [Joachim et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23706948/)
95. [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)
96. [Keenan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663139/)
97. [Khanani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37696275/)
98. [Khanani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41407269/)
99. [Khurana (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Khurana-MacSoc-2025-Central-Subdomains-.pdf)
100. [Khurana et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/10/AAO-2024-poster-final.pdf)
101. [Kim et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8236262/)
102. [Kimel et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27893095/)
103. [Klein et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2612630/)
104. [Krogh Nielsen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37933609/)
105. [Künzel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7405807/)
106. [Künzel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12872259/)
107. [Kuriyan et al. (2025)](https://annexonbio.com/wp-content/uploads/2025/05/04_11_2025_ARVO_-Kuriyan_FINAL.pdf)
108. [Lad (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Lad-MacSoc-2025-C1q-inhibition-GBS-HD-GA-.pdf)
109. [Lad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12882265/)
110. [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)
111. [Legge (2024)](https://optometricmanagement.com/issues/2024/may/coding-and-billing-for-geographic-atrophy/)
112. [Li et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712255/)
113. [Li et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976467/)
114. [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)
115. [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)
116. [McGuinness et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28139151/)
117. [Mitchell et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30303083/)
118. [Morga et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10011295/)
119. [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)
120. [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)
121. [Patel et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37572871/)
122. [Patel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38777140/)
123. [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)
124. [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)
125. [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)
126. [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)
127. [Prasad et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12803917/)
128. [Rahimy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232896/)
129. [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)
130. [Rein et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34560128/)
131. [Rein et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)
132. [Rim et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32344073/)
133. [Rowe et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42999938/)
134. [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)
135. [Sadda et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11366072/)
136. [Sambhara (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Sambhara-Hawaii-2026-Design-and-Rationale.pdf)
137. [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)
138. [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)
139. [Sarraf et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456394/)
140. [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)
141. [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)
142. [Schmitz-Valckenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5115977/)
143. [Sharma (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Sharma-Euretina.pdf)
144. [Shen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/31047226/)
145. [Shen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13474407/)
146. [Singh et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37847167/)
147. [Stanga (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Stanga-EURetina-2025-C1q-inhibition-HD-GA_.pdf)
148. [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf)
149. [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)
150. [Sunness et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9331210/)
151. [Sunness et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2562326/)
152. [Sunness et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18486216/)
153. [Tzoumas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10266126/)
154. [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)
155. [Vangsted et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37680141/)
156. [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)
157. [Vujosevic (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Vujosevic-EURetina-2025-Design-and-Rationale-ARCHER-II.pdf)
158. [Wang and Ying (2021)](https://pubmed.ncbi.nlm.nih.gov/32721951/)
159. [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=S01XA)
160. [WHO proposed INN List 134 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl134.pdf)
161. [WHO recommended INN List 96 (2026)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl96.pdf)
162. [Williams et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Williams-AAO-Vision-Loss-in-Eyes-with-Subfoveal-RPE-Lesions-in-GA-Post-Hoc-Analysis-of-the-ARCHER-Trial.pdf)
163. [Witkin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10786078/)
164. [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)
165. [Wykoff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40280279/)
166. [Xin et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28665868/)
167. [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
